EUVIMEDEUVIMED entdecken
Crossref

High Tacrolimus Intra‐Patient Variability and Adverse Outcomes in Cardiac Transplant Recipients: A Single‐Center Study in China

Zhenzhen Wang, Hua Zheng, Mian Zhang, Yibo Wang, Yunfei Liu, Dong Zeng, Hongxiang Zheng, Bin Yang, Lin Guo iD

Clinical Transplantation · 2026

DOI: 10.1111/ctr.70427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2026. Verfasst von Zhenzhen Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency and Critical Care Medicine, The Seventh People's Hospital of Zhengzhou, Zhengzhou, China. Hauptthemen laut MEDLINE: Tacrolimus, Heart Transplantation, Immunosuppressive Agents, Graft Rejection. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Project of Zhengzhou Medical and Health Science and Technology Innovation Awareness Plan, Joint Project of Henan Medical Science and Technology Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the association between tacrolimus intra‐patient variability (IPV) and the prognosis of cardiac transplant recipients.

Methods

Tacrolimus trough concentrations (C 0 ) from cardiac transplant recipients were collected during the postoperative months 3–6. Dose‐adjusted IPV values were calculated, and recipients were divided into high‐IPV and low‐IPV groups. The composite endpoint was defined as the occurrence of any one of the following: infection, rejection, or mortality.

Results

A total of 202 recipients were included. The incidence of infections was significantly higher in the high‐IPV group (34.8% vs. 21.1%, χ 2 = 4.480, p = 0.034). The risk of infection and composite endpoint occurrence was approximately 2.2 and 2.1 times higher, respectively, in the high‐IPV group than in the low‐IPV group, with hazard ratios (HR) and 95% CIs of 2.215 (1.175–3.842) and 2.061 (1.258–3.378). No significant differences were observed between the two groups in terms of rejection or mortality ( p > 0.05). Cox regression analysis revealed that the relative risk of composite endpoint occurrence in the high‐IPV group was 2.024 times higher than in the low‐IPV group. The cumulative event‐free survival rates for the composite endpoint differed significantly between the two groups. Log‐rank testing of the survival curves yielded p = 0.004 and HR = 2.061 (95% CI: 1.258–3.378).

Conclusion

Cardiac transplant recipients with high tacrolimus IPV may be at increased risk of adverse events such as infections. Tacrolimus IPV, which is simple to calculate, can serve as a useful follow‐up tool for predicting postoperative adverse outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusHeart TransplantationImmunosuppressive AgentsGraft RejectionPostoperative ComplicationsHumansMaleFemaleMiddle AgedFollow-Up StudiesPrognosisGraft SurvivalChinaRisk FactorsAdultRetrospective StudiesSurvival RateIncidenceTransplant Recipients

Stichwörter der Autor:innen

cardiac transplantationintra‐patient variabilityprognosissingle‐center studytacrolimus

Substanzen

TacrolimusImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Emergency and Critical Care Medicine, The Seventh People's Hospital of Zhengzhou, Zhengzhou, China.
  • Department of Heart Transplantation Center, The Seventh People's Hospital of Zhengzhou, Zhengzhou, China.

ORCID-Profile: Lin Guo

Förderung

  • Project of Zhengzhou Medical and Health Science and Technology Innovation Awareness Plan
  • Joint Project of Henan Medical Science and Technology Research Program

Zitieren

APA

Wang, Z., Zheng, H., Zhang, M., Wang, Y., Liu, Y., Zeng, D., Zheng, H., Yang, B., & Guo, L. (2026). High Tacrolimus Intra‐Patient Variability and Adverse Outcomes in Cardiac Transplant Recipients: A Single‐Center Study in China. Clinical Transplantation. https://doi.org/10.1111/ctr.70427

Vancouver

Wang Z, Zheng H, Zhang M, Wang Y, Liu Y, Zeng D, et al. High Tacrolimus Intra‐Patient Variability and Adverse Outcomes in Cardiac Transplant Recipients: A Single‐Center Study in China. Clinical Transplantation. 2026. doi:10.1111/ctr.70427

BibTeX
@article{Wang2026,
  author = {Wang, Zhenzhen and Zheng, Hua and Zhang, Mian and Wang, Yibo and Liu, Yunfei and Zeng, Dong and Zheng, Hongxiang and Yang, Bin and Guo, Lin},
  title = {High Tacrolimus Intra‐Patient Variability and Adverse Outcomes in Cardiac Transplant Recipients: A Single‐Center Study in China},
  journal = {Clinical Transplantation},
  year = {2026},
  doi = {10.1111/ctr.70427}
}
Kostenlos starten →